)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Dimerix
Dimerix (DXB) investor relations material
Dimerix Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary6 Aug, 2026
Strategic focus and innovation
Developing novel therapies for kidney diseases with significant unmet clinical needs, targeting both rare and high-risk indications.
Emphasizing diversification by geography and asset to reduce risk and enhance growth opportunities.
Integrating ESG principles into business operations and decision-making.
Product pipeline and clinical progress
DMX-200 is in Phase 3 for focal segmental glomerulosclerosis (FSGS), with recruitment completed and strong statistical power for efficacy.
DMX-652, a first-in-class USP30 inhibitor, is Phase 2 ready for acute kidney injury (AKI) in high-risk cardiac surgery patients, with a strong safety profile and FDA clearance.
Both assets leverage shared renal expertise and infrastructure, supporting efficient development and commercialization.
Commercial partnerships and revenue potential
Five commercial licensing partners for DMX-200 across major global markets, with deals valued up to AU $1.9 billion in upfront, milestone payments, and royalties.
Geographic diversification of revenue streams, with upfront and milestone payments totaling AU $318 million pre-launch.
Royalties range from 10% to 30% depending on territory and partner.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dimerix
- Phase 3 FSGS trial fully recruited; DMX-652 phase 2 ready; global deals up to AU$1.9B.DXB
Investor presentation27 Jul 2026 - DMX-200 advances in global FSGS trials, securing major licensing deals and strong market potential.DXBInvestor presentation16 Jun 2026
- Strong licensing income, robust cash reserves, and global trial progress position for future growth.DXBH2 202527 Mar 2026
- DMX-200 Phase 3 advances, major licensing deals, and strong cash position despite higher R&D loss.DXBH2 202427 Mar 2026
- Net loss widened to $15.97 million as R&D spending surged for the Phase 3 FSGS trial.DXBH1 20265 Mar 2026
- ACTION3 Phase 3 trial reached full recruitment; cash reserves support ongoing operations.DXBQ2 2026 TU29 Jan 2026
- Phase 3 trial nears full recruitment, with strong interim data, regulatory alignment, and global deals.DXBInvestor Update23 Nov 2025
- Cash reserves remain robust as clinical and regulatory milestones advance DMX-200 for FSGS.DXBQ1 2026 TU28 Oct 2025
- DMX-200 targets FSGS in Phase 3, with major licensing deals and key FDA milestones ahead.DXBInvestor Presentation20 Oct 2025
Next Dimerix earnings date
H2 202627 Aug, 2026
Dimerix
Next Dimerix earnings date
H2 202627 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage